[1] |
Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease[J]. Blood, 2014, 124(4):483-492.
URL
|
[2] |
Chester W. Uber Lipoidgranulomatose[J].Virchows Arch Pathol Anat, 1930,279:561-602.
|
[3] |
Jaffe HL. Lipid (cholesterol) granulomatosis. In: Jaffe HL, ed. Metabolic, degenerative and inflammatory diseases of bones and joints[M]. Philadelphia: Lea & Febiger, 1972:535-541.
|
[4] |
Binyousef RF, Al-Gahmi AM, Khan ZR, et al. A rare case of Erdheim-Chester disease in the breast[J]. Ann Saudi Med, 2017, 37(1):79-83.
|
[5] |
Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature[J]. Orphanet J Rare Dis, 2013, 8:137.
|
[6] |
Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease:comprehen-sive review of the literature and of 10 new cases[J]. Ann Rheum Dis, 2013, 72(10):1691-1695.
URL
|
[7] |
Abdelfattah AM, Arnaout K, Tabbara IA. Erdheim-Chester disease: a comprehensive review[J]. Anticancer Res, 2014, 34(7):3257-3262.
URL
|
[8] |
Tan AP, Tan LK, Choo IH. Erdheim-Chester disease involving breast and muscle: imaging findings[J]. AJR Am J Roentgenol, 1995,164(5):1115-1117.
|
[9] |
Furuta T, Kiryu S, Yamada H, et al. Erdheim-Chester disease with an 18F-fluorodeoxy-glucose-avid breast mass and BRAF V600E mutation[J]. Jpn J Radiol, 2014, 32(5):282-287.
URL
|
[10] |
Ferrozzi F, Bova D, Tognini G, et al. Pseudotumoral bilateral involvement of the breast in Erdheim-Chester disease: CT appearance[J]. J Comput Assist Tomogr, 2000, 24(2):281-283.
|
[11] |
Andrade VP, Nemer CC, Prezotti AN, et al. Erdheim-Chester disease of the breast associated with Langerhans-cell histiocytosis of the hard palate[J]. Virchows Arch, 2004, 445(4):405-409.
URL
|
[12] |
Barnes PJ, Foyle A, Haché KA, et al. Erdheim-Chester disease of the breast: a case report and review of the literature[J]. Breast J, 2005, 11(6):462-467.
|
[13] |
Provenzano E, Barter SJ, Wright PA, et al. Erdheim-chester disease presenting as bilateral clinically malignant breast masses[J]. Am J Surg Pathol, 2010, 34(4):584-588.
|
[14] |
Basara I, Yavuz E, Balci P, et al. Erdheim Chester disease presented isolated breast and axillary involvement[J]. JBR-BTR, 2015,98(2):82-84.
|
[15] |
Guo S, Yan Q, Rohr J, et al. Erdheim-Chester disease involving the breast-a rare but important differential diagnosis[J]. Hum Pathol, 2015, 46(1):159-164.
|
[16] |
Tomasini C, Soro E, Pippione M. Eyelid swelling: think of metastasis of histiocytoid breast carcinoma[J]. Dermatology (Basel), 2002, 205(1):63-66.
|
[17] |
Andrysek K. Erdheim-Chester disease: a case study and literature review[J]. Dimens Crit Care Nurs, 2011, 30(4):184-189.
|
[18] |
Green I, Dorfman RF, Rosai J. Breast involvement by extranodal Rosai-Dorfman disease: report of seven cases[J]. Am J Surg Pathol, 1997, 21:664-668.
|
[19] |
Cangi MG, Biavasco R, Cavalli G, et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease[J].Ann Rheum Dis, 2014, 74(8):1596-1602.
|
[20] |
Sebolt-Leopold J, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer[J]. Nat Rev Cancer, 2004, 4(12):937-947.
|
[21] |
Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patientswith BRAF(V600E)-mutated Erdheim-Chester disease[J]. J Clin Oncol, 2015, 33(5):411-418.
|
[22] |
Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single center series of 37 patients[J]. Blood, 2011, 117(10):2783-2790.
URL
|
[23] |
Srikulmontree T, Massey D, Roberts N. Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action[J].Rheumatol Int, 2007, 27(3):303-307.
URL
|
[24] |
Poiroux L, Paycha F, Polivka M, et al. Efficacy of zoledronic acid in Erdheim-Chester disease: A case report[J]. Joint Bone Spine, 2016, 83(5):573-575.
|